Kristen A. Johnson is a partner in Hagens Berman Sobol Shapiro's LLP Boston office. She sues drug companies for defrauding the public, violating antitrust laws, and injuring patients.
Ms. Johnson's recent successes include a $100+ million settlement for victims who contracted fungal infections from contaminated steroids compounded by New England Compounding Center. Ms. Johnson was also instrumental in the recent Flonase ($150 million), Wellbutrin XL ($37.5 million partial settlement), and Wellbutrin SR ($21.5 million) antitrust settlements.
Ms. Johnson is currently alternate lead counsel in the In re New England Compounding Pharmacy Litigation Multidistrict Litigation (MDL 2419). During the nascent stages of the MDL, Ms. Johnson was personally appointed liaison counsel to speak for the hundreds of victims who contracted fungal meningitis or suffered other serious health problems as a result of receiving contaminated products produced by NECC.
In 2011, Public Justice nominated Ms. Johnson and the rest of her trial team for Trial Lawyer of the Year for their work securing a $142 million RICO verdict against Pfizer for fraudulently marketing the drug Neurontin.
Ms. Johnson is actively involved in In re Nexium Antitrust Litigation (MDL No. 2409); In re Lipitor Antitrust Litigation (MDL No. 2332); In re Effexor XR Antitrust Litigation (District of New Jersey, No. 11-cv-5479); and In re Prograf Antitrust Litigation (MDL No. 2242).
Ms. Johnson graduated cum laude from Dartmouth College and earned her J.D. at Boston College Law School.
Ms. Johnson is admitted to practice in the Commonwealth of Massachusetts, the District of Massachusetts, and the First Circuit Court of Appeals. She is a member of the American Association for Justice and Public Justice's Class Action Preservation Project Committee.